Karadoğan Dilek, Kaya İlknur, Yumrukuz Şenel Merve, Konyalıhatipoğlu Esin Bilgin, Telatar Tahsin Gökhan, Akgün Metin
Department of Chest Diseases, School of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
Department of Chest Diseases, School of Medicine, Kütahya Health Sciences University, Kütahya, Türkiye.
Tob Induc Dis. 2024 Jan 23;22. doi: 10.18332/tid/176228. eCollection 2024.
Asthma and COPD management have a broad framework, and smoking cessation plays an essential role. We examine the management of asthma and COPD patients not only for inhaler treatment options but also for essential interventions, such as smoking cessation support.
Data were collected cross-sectionally from pulmonology departments of three government hospitals in Türkiye between May and September 2022. Patients aged ≥18 years who had been diagnosed with asthma or COPD for at least a year, were included in the study. The demographic and clinical characteristics of the patients were investigated. Routine cessation interventions were implemented for current smokers, and they were followed via phone calls after one month regarding their quit status and access to cessation clinics.
Data from 145 patients with asthma and 148 patients with COPD were analyzed. The rate of current smoking among patients with asthma and COPD was 18.8% and 34.5%, respectively. Current smoking was negatively associated with age (<65 years) and disease duration (years) for both diseases (p<0.05). In addition, for asthmatics, presence of pulmonary disease in the family (OR:0.28, 95% CI: 0.10-0.79) and for COPD patients presence of hospitalization (OR: 0.26, 95% CI: 0.07-0.93) were negatively associated with current smoking. After one month, 85.1% of current asthmatic smokers had not tried to call a quitline, while 14.8% had tried to contact a quitline. Among current smoker COPD patients, only 1.9% had visited a smoking cessation clinic.
Tobacco cessation support seems to be neglected in asthma and COPD management. Instead, pulmonologists and patients focus on pharmaceutical treatments, which constitute the other component of care.
哮喘和慢性阻塞性肺疾病（COPD）的管理有一个广泛的框架，戒烟起着至关重要的作用。我们不仅研究哮喘和COPD患者的吸入器治疗选择，还研究基本干预措施，如戒烟支持。
2022年5月至9月期间，从土耳其三家政府医院的肺病科进行横断面数据收集。年龄≥18岁、被诊断为哮喘或COPD至少一年的患者被纳入研究。调查了患者的人口统计学和临床特征。对当前吸烟者实施常规戒烟干预，并在一个月后通过电话跟踪他们的戒烟状态以及是否能前往戒烟诊所。
分析了145例哮喘患者和148例COPD患者的数据。哮喘和COPD患者当前的吸烟率分别为18.8%和34.5%。两种疾病中，当前吸烟与年龄（<65岁）和病程（年）均呈负相关（p<0.05）。此外，对于哮喘患者，家族中有肺部疾病（比值比：0.28，95%置信区间：0.10 - 0.79），对于COPD患者，有住院史（比值比：0.26，95%置信区间：0.07 - 0.93）与当前吸烟呈负相关。一个月后，85.1%的当前哮喘吸烟者未尝试拨打戒烟热线，而14.8%的人曾尝试联系戒烟热线。在当前吸烟的COPD患者中，只有1.9%的人去过戒烟诊所。
在哮喘和COPD管理中，戒烟支持似乎被忽视了。相反，肺科医生和患者专注于药物治疗，而药物治疗是护理的另一个组成部分。
